VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects. ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyt ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Morgan Stanley analyst Chris Quintero raised the firm’s price target on Vertex (VERX) to $62 from $50 and keeps an Overweight rating on the shares. The firm has greater conviction in Vertex being a ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

Gilead Sciences has a Zacks Rank of #2 (Buy), while Vertex Pharmaceuticals has a Zacks Rank of #3 (Hold ... The P/B ratio is used to compare a stock's market value with its book value, which is ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

The stock market awaits reports from Home Depot, Disney and Cisco Systems. Cisco, Costco and Vertex are in buy zones.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...